Drug Discovery World

FEBRUARY 21, 2023

Charles River Laboratories and Pioneering Medicines have entered a multi-programme agreement that gives Pioneering Medicines access to artificial intelligence (AI) model Logica.

Small Molecule 130

Small Molecule DNA Drugs Laboratories 130

DrugBank

JULY 24, 2024

These multifunctional small molecules are like tiny spies, hijacking the body’s natural protein degradation system to remove unwanted proteins. For example, PROTACs targeting STAT3, a protein crucial for tumor growth, have shown promise where conventional therapies have failed.

Small Molecule 84

Small Molecule Clinical Trials Drugs Therapies 84

Drug Discovery World

DECEMBER 21, 2023

In a record year for gene therapy approvals, it isn’t surprising that cell & gene therapy (CGT) has been a hot topic. Three trends in the antibody-drug conjugate (ADC) market Antibody-drug conjugates are biopharmaceutical products in which a monoclonal antibody (mAB) is linked to a small molecule drug with a stable linker.

FDA Approval 148

FDA Approval Therapies Small Molecule Clinical Trials 148

Drug Discovery World

SEPTEMBER 6, 2022

DDW Editor Reece Armstrong looks at the cell and gene therapy landscape, examining the challenges facing developers and the trends we can expect to see throughout the year. . There’s no doubt that cell and gene therapies present some of the most exciting opportunities for emerging drugs. million price point per dose.

Therapies 130

Therapies Clinical Trials Vaccine Disease 130

DrugBank

MAY 15, 2024

One approach is to look beyond the traditional drug molecule. Researchers are experimenting with biologics—larger biological molecules that can do things small molecules can't, like targeting larger, more complex structures on cell surfaces or even inside cells.

Small Molecule 83

Small Molecule Molecular Biology Drugs Disease 83

Drug Discovery World

APRIL 8, 2024

Bold Therapeutics’ BOLD-100, a ruthenium-based small molecule, acts by targeting GRP78 to modulate the unfolded protein response (UPR) and by generating reactive oxygen species (ROS) leading to DNA damage and cell cycle arrest.

DNA 130

DNA Small Molecule Science Treatment 130

Drug Target Review

APRIL 16, 2024

Can you explain how Radioligand Therapy (RLT) is applicable in the treatment of both chemotherapy-resistant tumours and in naïve patients who have not undergone prior cancer treatment? By delivering radiation directly to the tumour cells, RLT can induce DNA damage, leading to cell death and tumour regression.

Small Molecule 59

Small Molecule Therapies Treatment Pharmaceutical Companies 59

Drug Target Review

NOVEMBER 6, 2023

2 It is this complexity that necessitates powerful, targeted combination therapies. 4, 5 More recently, new combination regimens have emerged that incorporate targeted therapies to treat a variety of blood cancers, including multiple myeloma (MM), chronic lymphocytic leukaemia (CLL) and acute myelogenous leukaemia (AML).

Small Molecule 111

Small Molecule Therapies Treatment Immune Response 111

Drug Target Review

JULY 18, 2024

We believe liquid biopsy is very helpful for oncology drug development because the reduction and clearance of circulating DNA occurs quickly before radiographic imaging is available. The initial techniques were able to detect circulating tumour DNA in patients who already had metastatic spread.

Drug Development 59

Drug Development Clinical Trials Small Molecule Vaccine 59

Covalent Modifiers

AUGUST 14, 2023

Acquired cysteines are both driver mutations and sites targeted by precision therapies. For both cancer and healthy genomes, we find that cysteine acquisition is a ubiquitous consequence of genetic variation that is further elevated in the context of decreased DNA repair.

Small Molecule 52

Small Molecule RNA DNA Therapies 52

The Pharma Data

MAY 15, 2023

Through the acquisition, Gilead gains rights to a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases that could enter clinical trials later this year. Executive Vice President, Research, Gilead Sciences. The company was founded in 2021 by Stephen Kaldor, Ph.D., Qing Dong, Ph.D.,

Small Molecule 40

Small Molecule DNA Immune Response Science 40

LifeSciVC

DECEMBER 6, 2022

These hair clip-like molecules clamp onto DNA, thereby turning many genes on and off. Darnell’s 2002 paper Transcription Factors as Targets for Cancer Therapy , in which he wrote: “A limited list of transcription factors are overactive in most human cancer cells, which makes them targets for the development of anticancer drugs.

Small Molecule 40

Small Molecule DNA Regulations Science 40

Drug Discovery World

OCTOBER 16, 2023

A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. CellProthera also appointed the Newcastle Centre for Life’s GMP cell therapy centre to produce the ATMP.”

Drugs 190

Drugs Science Therapies Targeted Protein Degradation 190

The Pharma Data

JUNE 28, 2021

Broadens company’s oncology platform of Targeted Alpha Therapies / Acquisition includes actinium-225 labeled differentiated PSMA small molecule for the treatment of prostate cancer. It has been demonstrated to inflict difficult to repair damage to tumor cells by inducing DNA double strand breaks.

Small Molecule 52

Small Molecule Licensing Licensing Therapies 52

Drug Discovery World

APRIL 30, 2024

Reece Armstrong explores the potential and future opportunities for mRNA-based therapies. For instance, consider how at the end of 2018, the mRNA therapies market was valued at $3.43 At the start of 2024, the first patients in a clinical trial investigating an mRNA cancer therapy were dosed.

Therapies 130

Therapies RNA Vaccine Small Molecule 130

DrugBaron

JULY 19, 2022

Despite the current hype around so called “advanced therapies”, which range from gene editing to cell therapies, and the inexorable advance of biologic therapeutics such as monoclonal antibodies, even in 2022 the majority of drugs in development and reaching patients are still small organic molecules.

Small Molecule 100

Small Molecule Drugs DNA Pharma Companies 100

Drug Discovery World

APRIL 15, 2023

Sunday, April 16, 2023, 1:30-5:00pm ET MDSC-targeted TFF2-MSA synergizes with PD-1 blockade therapy in diffuse-type gastric cancer – Jin Qian, et al. BDC-3042 is an agonistic antibody targeting Dectin-2, an immune-activating receptor expressed by TAMs. wt murine colorectal cancer models – Bruce L Daugherty, et al.

Virus 130

Virus Clinical Trials Trials Therapies 130

Dark Matter Blog

JULY 16, 2021

As soon as I learned about DNA and RNA, I wanted to be a molecular biologist. Last stops at RNA My last roles in biotech were where my original passion began: DNA and RNA. My last stop at Arrakis Therapeutics is with a company targeting RNA with small molecules. I wanted to use molecular biology to create drugs.

Small Molecule 52

Small Molecule RNA Clinical Trials DNA 52

Drug Discovery World

JUNE 5, 2023

Megan Thomas caught up with Debora Lucarelli, CEO of Enhanc3D Genomics, to learn more about the company. She said: “We are a functional genomics company with a proprietary platform that allows us to charter the non-coding DNA, from which we extract a lot of valuable information to identify novel targets and biomarkers.

Small Molecule 130

Small Molecule Treatment Science Disease 130

LifeSciVC

MARCH 1, 2023

Augustin et al summarized how novel platforms have more recently been applied to try to solve this question including CRISPR genome editing combined with adoptive cell therapy, siRNA knockdown, DNA encoded library approaches and machine learning algorithms.

Small Molecule 52

Small Molecule Immune Response DNA Therapies 52

The Pharma Data

APRIL 11, 2023

Bayer is advancing its oncology R&D efforts in three scientific areas that have the potential to address unmet needs in cancer patients: next-generation Immuno-Oncology, Targeted Radionuclide Therapies and Precision Molecular Oncology. Data from all three areas of scientific focus will be showcased during this year’s meeting.

Research 40

Research Clinical Trials Small Molecule Pharmacokinetics 40

The Pharma Data

MARCH 7, 2022

The new technique controls gene activity without altering the DNA sequence of the genome by targeting chemical modifications that help package genes in our chromosomes and regulate their activity. In this experiment, however, the cutting function of the Cas9 protein is disabled so the genomic DNA sequence is unaltered.

RNA 52

RNA DNA Packaging Small Molecule 52

The Pharma Data

DECEMBER 14, 2020

. The current standard of care for GBM consists of de-bulking surgery followed by combined treatments with fractionated ionizing radiation (IR) and the DNA alkylating agent temozolomide (TMZ). At the stage of GBM relapse and recurrence, no effective therapy strategies currently exist. Contact.

DNA 52

DNA Clinical Trials Drugs Therapies 52

The Pharma Data

MARCH 18, 2022

By manipulating the microbes’ DNA, they programmed gene circuits that control the bacteria surface, building a molecular “cloak” that encapsulates the bacteria. They control the iCAP system by giving it an external cue – a small molecule called IPTG – that allows for programmable and dynamic alteration of the E.

Engineering 52

Engineering Small Molecule Drugs Therapies 52

The Pharma Data

NOVEMBER 18, 2020

The company’s novel first-in-class AKR1C3 targeted therapy is OBI-3424 (small-molecule prodrug) that selectively releases a potent DNA alkylating agent in the presence of the aldo-keto reductase 1C3 (AKR1C3) enzyme. Additional information can be found at www.obipharma.com.

Vaccine 52

Vaccine Small Molecule Immune Response Hospitals 52

Drug Discovery World

FEBRUARY 29, 2024

In the first article, Reece Armstrong speaks to Natalia Mateu, Co-Founder, Jelena Aleksic, Co-Founder and Peter Curran, Chemoinformatics Scientist, about utilising 3D chemistry and AI to get small molecule therapies from the clinic to the bedside.

Small Molecule 130

Small Molecule DNA Therapies Production 130

Drug Discovery World

JULY 8, 2024

For decades, the life sciences community held the belief that RNA was merely the intermediary messenger (mRNA) between DNA and protein, a dogma that has been the foundation of biology. The most developed RNAi is small interfering ribonucleic acid (siRNA)-based therapies. These are critical attributes for acute care applications.

RNA 148

RNA Small Molecule Vaccine FDA Approval 148

Drug Discovery World

FEBRUARY 29, 2024

In the first article, Reece Armstrong speaks to Natalia Mateu, Co-Founder, Jelena Aleksic, Co-Founder and Peter Curran, Chemoinformatics Scientist, about utilising 3D chemistry and AI to get small molecule therapies from the clinic to the bedside.

Small Molecule 130

Small Molecule DNA Therapies Production 130

Codon

JUNE 11, 2024

And unlike traditional DNA sequencers, which parse genetic material by breaking it up into fragments and interpreting it chunk-by-chunk, a nanopore device unspools a long strand of DNA and reads it all at once. A scientist can isolate DNA and load up a flow cell in fifteen minutes. Nanopore devices work incredibly fast.

DNA 80

DNA Engineering RNA Small Molecule 80

Drug Discovery World

NOVEMBER 15, 2022

Rapid and accurate DNA synthesis . Conventional DNA synthesis, typically used for making sequences such as primers, employs phosphoramidite chemistry, a method that was developed in the 1980s and is still considered the gold standard for DNA synthesis. .

DNA 246

DNA Engineering Drugs Vaccine 246

The Pharma Data

DECEMBER 27, 2020

NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today provided a year-end review and an outline of its plans for 2021. CARLSBAD, Calif.–( –( BUSINESS WIRE )– Lineage Cell Therapeutics, Inc.

Therapies 52

Therapies Clinical Trials Production Treatment 52

Drug Discovery World

APRIL 29, 2024

Jean-Baptiste Agnus, Chief Business Officer, and Peter Carbone, Chief Quality Officer, KBI Biopharma: Agnus brings more than two decades of experience in the biopharmaceutical industry with expertise in biologics, small molecule APIs, antibody-drug conjugates (ADCs), and cell and gene therapies.

Drugs 130

Drugs Small Molecule Bioinformatics Pharmaceuticals 130

Drug Discovery World

JUNE 6, 2023

His work has led to crucial insights into the understanding of the mechanisms by which T cells distinguish tumour cells from normal cells and has fueled the advancement of adoptive T-cell therapy approaches in various cancers, including leukemia and pancreatic cancer. From that, we’ll understand better how to use targeted therapies.”

Small Molecule 130

Small Molecule DNA RNA Research 130

Drug Target Review

OCTOBER 4, 2023

2 In response, DNA-damaging agents that could target the entire cell cycle received renewed attention as ADC payloads. Groundbreaking strategies like proteolysis-targeting chimeric molecules (PROTACs) are also being explored. 4 But the horizon of ADCs is expanding even further, with the design of complex payloads.

Small Molecule 126

Small Molecule Drugs Immune Response Targeted Protein Degradation 126

Drug Discovery World

FEBRUARY 2, 2023

Designed and developed by the privately held, dual platform-based biopharmaceutical company, EpicentRx, in collaboration with a major multinational American aerospace and defense contractor, RRx-001 is a Jekyll-and-Hyde small molecule, which in the manner of a Dr Jekyll benignly confers protection on normal tissues under normal oxygen conditions.

Small Molecule 130

Small Molecule Clinical Trials Disease Therapies 130

Codon

APRIL 2, 2023

But now, by studying DNA extracted from microbes in the blood of almost 10,000 healthy people, this paper shows that there is no such thing. Read Transcription factors bind to DNA and control gene expression. Read Switchable hydrophobic pockets in DNA protocells enhance chemical conversion. Nature Microbiology. Meeussen J.V.W.

DNA 52

DNA RNA Engineering Licensing 52

Drug Discovery World

JANUARY 12, 2023

The genome is the blueprint for life, consisting of genes made up of thousands of pairs of DNA bases. The development of CRISPR has opened the door to ending diseases by fixing mutations and developing therapies through the process of modeling mutations. They can also be used to develop better cell therapies, including T cell therapy.

Drugs 246

Drugs Disease Drug Development Therapies 246